GAFA
RDY icon

Garton & Associates Financial Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Garton & Associates Financial Advisors’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-155
Closed -$2.18K – 570
2025
Q4 		$2.18K Buy
+155
New +$2.17K ﹤0.01% 1091

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Garton & Associates Financial Advisors's RDY Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Dr. Reddy's Laboratories (RDY) in Q1 2026, closing a stake of 155 shares — an estimated $2.18K sold.

Garton & Associates Financial Advisors first reported a position in RDY in Q4 2025 and held it in 1 quarter. The position peaked at $2.18K in Q4 2025. 249 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining Dr. Reddy's Laboratories position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 155 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $2.18K.
  • Garton & Associates Financial Advisors first reported a position in Dr. Reddy's Laboratories in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's Dr. Reddy's Laboratories position peaked at $2.18K in Q4 2025.
  • 249 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.